Newsletter
Every new paper in this field, in your inbox.
Complete cytoreduction can significantly improve survival and relieve symptoms in patients with small intestinal neuroendocrine tumors metastatic to the liver and peritoneum. Despite initial controversies, achieving complete cytoreduction yielded comparable outcomes in patients with isolated liver metastases and those with liver and peritoneal metastases. Aggressive…
Population-based analysis shows lower overall 5-year survival rates in geriatric gastrointestinal stromal tumor patients compared to non-geriatric patients. Surgery significantly improves survival rates in both groups, with geriatric patients having higher hazard death ratio. Clinical management for geriatric patients may benefit from large prospective studies.
Researchers investigated the efficacy and safety of endoscopic resection (ER) for gastric gastrointestinal stromal tumors (GISTs) originating from the muscularis propria (MP). The study included 233 patients who underwent ER, with a median tumor size of 12 mm. The complete resection rate was 93.1%, with…
A nomogram incorporating treatment data proved better than the AJCC staging system in predicting overall survival for gastroenteropancreatic neuroendocrine tumors. Key factors include sex, age, race, tumor location, and treatment modalities. Internal and external validation showed superior performance, advocating for individual risk evaluation to enhance…
Experts from the European Society of Endocrine Surgeons provide evidence-based recommendations for surgery in advanced small bowel neuroendocrine tumours, addressing key controversial topics such as primary tumour resection, cytoreduction, lymph node clearance, and management of unknown primary tumours. The recommendations, based on a systematic literature…
This editorial highlights remarkable advancements in tailored medical treatment strategies for pancreatic neuroendocrine tumors. Cytoreductive surgery and somatostatin analogs are key in managing tumors, with additional treatment options available for refractory patients. Different subtypes require distinct therapeutic approaches, and ongoing research on the genetic basis…
An analysis of 34 cases of ischiorectal fossa tumors over a 30-year period found a high recurrence rate, with 35% of patients experiencing recurrence even after R0 resection. The median follow-up was 23 months, and the median time to recurrence was 6.5 months. Although there…
Study evaluates optimal treatment strategies for nonfunctioning small pancreatic neuroendocrine neoplasms, highlighting the impact of tumor size and grade on lymph node metastasis, recurrence, and survival. Personalized treatment approaches considering tumor grading are recommended for heterogeneous nf-spnens. Tumor size >20 mm for net-g1 and >10…
Gastric neuroendocrine neoplasms (GNENs) exhibit unique characteristics based on their type. Incidence is rising, with GNENs including carcinomas and tumors. Different types require distinct approaches, with type III often needing locoregional and systemic treatments. Treatment data is limited, but insights from other neuroendocrine tumors are…
Updated nomograms for primary retroperitoneal sarcoma patients differ in survival outcomes between high and low-volume centers. Case volume significantly influences overall and disease-free survival and nomogram performance. High-volume centers demonstrate better calibration than low-volume centers. Case volume should be considered in prognostic nomogram development for…
